FDA in the dock over drug scandals
US officials attempted to restore the reputation of the pharmaceutical industry by announcing plans to introduce an independent board, which aims to monitor the safety of drugs on the market.
Archives for February 16, 2005
Sigma-Aldrich introduces gene knockout system
Sigma-Aldrich introduces the TargeTron gene knockout system, a tool that is set to feature prominently in functional genomics and systems biology. It incorporates technology that exploits the retrohoming ability of group II introns, which "target" the...
Big pharma missing the nanotechnology boat?
The top pharmaceutical companies are investing less money and people in nanotechnology than other industries, despite pressure to replace fading blockbuster drugs as fewer drugs come out of the sector's R&D pipeline, according to market research.
New HT service accelerates cellular target screening
A new high throughput ion channel screening service has been launched by BioFocus, which will allow pharmaceutical companies to pre-screen libraries against defined cell lines, identifying target compounds and limiting the use of more time-consuming...
Safer cell culture supplement launched
Recently-formed cell culture specialist Celliance has introduced a new supplement designed to boost the growth of cells used in research and bioprocessing, that does not contain fetal bovine serum.
Biocompatibles plans next-generation microspheres
UK company Biocompatibles has teamed up with a microfluidics specialist Q Chip to develop a system to improve the manufacture of microspheres used in drug delivery and medical devices.
Neurodegeneration treatments identified in study
Researchers in the US have identified several promising drug compounds, which when combined, show the potential to treat Huntingdon's and other neurodegenerative diseases.
Pharma firms evaluate laser marking of tablets
UK laser marking specialist Sherwood Technology now has two pharmaceutical companies evaluating its DataLase technology, an additive that can be used to mark tablets.
Big pharma missing nanotechnology opportunities
A new report reveals that large pharmaceutical companies are investing in less money and people in nanotech than other industries, despite pressure to replace fading blockbuster drugs.